Summary
Bristol Myers Squibb (BMY) has filed its second quarter 2025 10-Q, providing investors with an update on its financial performance and operational developments. The report covers the period ending June 29, 2025, and highlights the company's ongoing focus on strategic growth initiatives and product portfolio management. Investors should pay close attention to the company's revenue trends, research and development investments, and any updates on key litigation or regulatory matters that could impact future performance.
Financial Highlights
55 data pointsBeta
Financial Statements
Beta
| Revenue | $12.27B |
| Cost of Revenue | $3.37B |
| Gross Profit | $8.90B |
| R&D Expenses | $2.58B |
| SG&A Expenses | $1.71B |
| Operating Expenses | $10.50B |
| Net Income | $1.31B |
| EPS (Basic) | $0.64 |
| EPS (Diluted) | $0.64 |
| Shares Outstanding (Basic) | 2.04B |
| Shares Outstanding (Diluted) | 2.04B |
Key Highlights
- 1The report details the company's financial performance for the second quarter of 2025, with specific focus on revenue generation and profitability.
- 2Key updates on the company's product pipeline and R&D investments are provided, indicating continued commitment to innovation.
- 3Management's Discussion and Analysis section offers insights into the operational drivers and strategic decisions impacting the company's financial results.
- 4Information regarding legal proceedings and risk factors is presented, which could pose potential challenges or opportunities for BMY.
- 5The filing includes the consolidated financial statements, offering a comprehensive view of the company's assets, liabilities, and equity as of the reporting period.
- 6Consolidated statements of cash flows will provide investors with clarity on the company's cash generation and utilization activities during the quarter.
Frequently Asked Questions
The 10-Q filing details the revenue performance across BMY's product portfolio. Investors should review the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' section for a breakdown of revenue by product and therapeutic area, identifying which drugs contributed most significantly to top-line growth or experienced declines.
The Consolidated Balance Sheets provide a snapshot of BMY's financial health as of June 29, 2025, detailing assets, liabilities, and shareholders' equity. The Consolidated Statements of Cash Flows will further elaborate on the company's ability to generate cash from operations, invest in its business, and manage its financing activities, offering insights into its liquidity position.
Item 1. Legal Proceedings and Item 1A. Risk Factors in Part II of the 10-Q address any ongoing or potential legal actions and significant risks the company faces. Investors should carefully review these sections for any material information that could impact the company's financial standing or future operations.
While the 10-Q primarily focuses on financial results, updates on R&D investments and pipeline progress are often discussed within the 'Management's Discussion and Analysis' section. Investors should look for commentary on key clinical trial advancements, regulatory submissions, or new drug approvals that could influence future revenue streams.